Thomas E. Mürdter
Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Stuttgart
Germany
Name/email consistency: high
- Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Mürdter, T.E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P.A., Fehm, T., Eichelbaum, M., Schwab, M., Brauch, H. Clin. Pharmacol. Ther. (2011)
- Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. Mürdter, T.E., Friedel, G., Backman, J.T., McClellan, M., Schick, M., Gerken, M., Bosslet, K., Fritz, P., Toomes, H., Kroemer, H.K., Sperker, B. J. Pharmacol. Exp. Ther. (2002)









